Solutions For Healthcare Providers
iLink® is the first and only FDA-approved corneal cross-linking procedure that slows or halts the progression of keratoconus and helps preserve vision.
Watch this video for unique patient and doctor perspectives about progressive keratoconus and learn how this underserved patient population with a rare and sight-threatening condition is treated with iLink® corneal cross-linking.
Explore The Results of Our Clinical Study Data
In clinical studies, cross-linking–treated eyes showed increasing improvement in Kmax from month 3 through month 12, while in untreated, sham eyes, Kmax demonstrated steepening.3
If it’s not iLink®, it’s not FDA approved
When it comes to referring patients with progressive keratoconus for treatment, iLink® is the only FDA-approved corneal cross-linking procedure.
Explore Patient Resources for Keratoconus
View Patient Website
Looking for reimbursement info? The iPath360 program provides strategic and trustworthy market access solutions for all Glaukos procedures and products in glaucoma, corneal health, and retinal disease care.
Resources for Healthcare Professionals
Learn More About iLink® from the Experts
Order print versions of our practice marketing materials, including educational resources on keratoconus and FDA-approved cross-linking. You can also download digital versions of many of our educational resources.
Contact Us Today
to Integrate the iLink®
Procedure Into Your
Explore additional information about iLink® in our digital brochure and learn how the procedure is transforming the standard of care for progressive keratoconus.
- Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology. 2006;113(9):1633-1638.
- Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. Eye Contact Lens. 2014;40(6):382-389.
- Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016.